I will NEVER let this product run out in my house. As soon as it arrived I rubbed some on my sore neck and within two minutes I could feel the relief. I also have recently lost 145 pounds and cannot sit for long periods of time without my tailbone hurting (less rump padding) … last night I rubbed a very small amount on my tailbone and it helped sooo much! We have been doing a LOT of gardening and home improvement projects as its finally spring here in Michigan and I have used it on my achy hands and feet and my husbands shoulders and neck also… totally convinced this product can easily replace our regular OTC pain killer products. You really don’t need a ton either. Just a dab will do ya!
In June 2018, the FDA approved the drug Epidiolex, an oral preparation of pure CBD for treatment of two rare and severe forms of epilepsy in children. The drug is made by the GW Pharmaceutical Company and was tested in three randomized, double-blind, placebo-controlled clinical trials, including 516 patients. It was found to be effective in reducing the frequency of seizures.
Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid. In strongly basic media and the presence of air, it is oxidized to a quinone. Under acidic conditions it cyclizes to THC, which also occurs during pyrolysis (smoking). The synthesis of cannabidiol has been accomplished by several research groups.
A. The FDA is aware that several states have either passed laws that remove state restrictions on the medical use of marijuana and its derivatives or are considering doing so. It is important to conduct medical research into the safety and effectiveness of marijuana products through adequate and well-controlled clinical trials. We welcome the opportunity to talk with states who are considering support for medical research of marijuana and its derivatives to provide information on Federal and scientific standards.
While there are more unknowns than knowns at this point, Grant says he doesn’t discount all the anecdotal CBD reports. “You hear somebody say, ‘Hey, I gave this to myself and my kid and we feel a lot better,’ and we should never dismiss that kind of information,” he says. He points out that many modern medicines were discovered when researchers followed up on exactly this sort of human trial-and-error evidence. “But we still need to do the studies that confirm whether all the good things are true, and how much to give, and how to give it,” he says. “These are all questions that need to be answered.”
While research into the effects of CBD on specific conditions is important, a broader perspective on the relationship between CBD and the human body is necessary to understand how this unique compound works. Interestingly, many of the conditions that are supposedly helped by CBD have no well-understood cause, from acne to Alzheimer’s disease. However, one of the few common denominators between these conditions is the involvement of the endocannabinoid system (ECS) in their causes.
I’ve been wanting to know on how to understand the life cycle of a marijuana plant but I don’t know how to get started. I do research on my own, I also read lots of articles but this one caught my attention https://www.bonzaseeds.com/blog/life-cycle-marijuana-plant/ It has the content of all you about to know in planting and to understand the life cycle of marijuana plant.
Hemp oil is a "drying oil", as it can polymerize into a solid form. Due to its polymer-forming properties, hemp oil is used on its own or blended with other oils, resins, and solvents as an impregnator and varnish in wood finishing, as a pigment binder in oil paints, and as a plasticizer and hardener in putty. It has uses similar to linseed oil and characteristics similar to tung oil.
Cannabis is mostly used for recreation or as a medicinal drug, although it may also be used for spiritual purposes. In 2013, between 128 and 232 million people used cannabis (2.7% to 4.9% of the global population between the ages of 15 and 65). It is the most commonly used illegal drug both in the world and the United States. The countries with the highest use among adults as of 2018 are Zambia, the United States, Canada, and Nigeria. In 2016, 51% of people in the United States had ever used cannabis. About 12% had used it in the past year, and 7.3% had used it in the past month.
Subsequent studies were carried out in different countries, which confirmed the results found in the Zammit et al. (2002) study, showing that those clinically dependent on cannabis by 18 years of age had an increased risk of later developing psychotic symptoms (Fergusson, Horwood, & Swain-Campbell, 2003). Cannabis users were also more likely to develop schizophreniform disorder (Arseneault et al., 2002), and the dose–response relationship found in the first study was confirmed (Henquet et al., 2005).
Children and young teens start using marijuana for many reasons. Curiosity and the desire to fit into a social group are common motivating factors. Young people who have already begun to smoke cigarettes and/or use alcohol are at high risk for marijuana use. They may have family problems or a network of friends who use drugs and urge them to do the same (peer pressure).
About 9% of those who experiment with marijuana eventually become dependent according to DSM-IV (1994) criteria. A 2013 review estimates daily use is associated with a 10-20% rate of dependence. The highest risk of cannabis dependence is found in those with a history of poor academic achievement, deviant behavior in childhood and adolescence, rebelliousness, poor parental relationships, or a parental history of drug and alcohol problems. Of daily users, about 50% experience withdrawal upon cessation of use (i.e. are dependent), characterized by sleep problems, irritability, dysphoria, and craving. Cannabis withdrawal is less severe than withdrawal from alcohol.
And like many new sectors, the cannabis business has already seen its share of shareholder manipulation and self-dealing by executives, as MarketWatch has reported. Just last week, Aphria Inc. said an investigation of acquisitions in Argentina, Colombia and Jamaica found that some directors had conflicts of interest. The company’s CEO Vic Neufeld and co-founder Cole Cacciavillani are leaving their roles in March, although they will stay on as advisers.
One of the most experienced practitioners in this field is Los Angeles physician Bonni Goldstein, who has used the compound to treat dozens of children with intractable epilepsy. She says about half of these patients have seen a significant drop in the number of seizures. “Used in the right way, with the right patient, CBD is extremely powerful,” she says.
In a section devoted to CBD, or cannabidiol, analysts predict that the U.S. Food and Drug Administration will move to update its stance on the non-psychoactive ingredient found in cannabis and hemp that is widely held to have wellness properties. The recent U.S. 2019 Farm Bill fully legalized hemp for commercial use, but the FDA has retained a ban on adding CBD to food or drinks because it has not been fully researched. The agency has issued guidelines for the many companies eager to launch CBD-infused drinks and food products and has promised public talks on the matter, but for now companies are in a state of limbo.
Of course, though, they offer less potent oils than that, with a product lineup that ranges from 300 mg CBD per bottle to 4,000 mg. Naturally the 4,000 mg option is the most expensive (this is the one that provides the “bomb” 60 mg dose), as it currently sells for $299. For long-term pain and anxiety relief, though, it may be well worth it if it is effective for you and helps replace your regular meds.
Results of a Phase III study (N = 177) comparing Sativex, THC-predominant extract and placebo in intractable pain due to cancer unresponsive to opiates (Johnson and Potts 2005) demonstrated that Sativex produced highly statistically significant improvements in analgesia (Table 1), while the THC-predominant extract failed to produce statistical demarcation from placebo, suggesting the presence of CBD in the Sativex preparation was crucial to attain significant pain relief.
Whether the chronic pain is in your back, neck, hands, feet, or elsewhere – CBD can help! In order to understand how CBD helps provide pain relief, we turn to a series of medical studies that have been conducted over the past ten years. These studies evaluated CBD’s medical efficacy in treating those who suffer from various types of pain. We will address the results below.
Hemp and Marijuana come form the same plant family, but are completely different in function, cultivation and application. Marijuana generally has a high level of THC (a psychoactive compound that makes you feel “high”) and is used for medicinal or recreational purpose. Hemp contains a negligible amount of THC (but is high in CBD) and is used in dietary supplements, skin products, clothing and paper.
In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
As of 2018, there are a total of 46 states (including the 8 states mentioned above) where CBD is legal with a prescription for medicinal usage. Now although CBD usage is for legal in these states, the law varies from state to state, with 17 states having specific legislation for the THC-levels found in CBD and the conditions being treated with CBD.
Note that the federal definition of hemp requires that it contain less than 0.3% delta-9-tetrahydrocannabinol (THC), the euphorigenic component of cannabis. And while the terms “cannabis” and “marijuana” are often used interchangeably, the Controlled Substances Act of 1970 specifically excluded the mature stalks of the cannabis plant used in industrial applications — essentially hemp — from its definition of marijuana.
Been using product for a few days now ,I'm about one my 6th dose. I noticed today my hand from nerve damage has not dropped anything or felt numb,or even trembled. Even axienty has been managable. However I'm taking 250mgs.I boosted it up to 500mgs.3 or 4 times daily ,of 250mgs. It seems to have best effect atleast today.It's cold and rainy which,is better than snow ,is my most hightened pain days.Today 4/24/18. Has been a God send! 1 pain and axienty day free ...Makes me a believer! I stand by this products effectiveness. Hope my review helps another soul,that lives with same aliments.
The earliest recorded uses date from the 3rd millennium BC. Since the early 20th century, cannabis has been subject to legal restrictions. The possession, use, and sale of cannabis is illegal in most countries of the world. Medical cannabis refers to the physician-recommended use of cannabis, which takes place in Canada, Belgium, Australia, the Netherlands, Germany, Spain, and 31 U.S. states. In September 2018, cannabis was legalized in South Africa while Canada legalized recreational use of cannabis in October 2018.
Several hundred million years ago mosses and their kin went one way, evolutionarily speaking, and the lineage of trees and flowering plants went the other. Somehow, in the vast expanse of geologic time that followed, a few members of these distantly related groups in the plant kingdom copied one another in making something of great interest to humans: the psychoactive chemical, or cannabinoid, that gets people high.
The HPRA is the competent authority for authorising medicinal products in Ireland. Its role is to ensure that only products that are safe, effective and of an appropriate quality based on clinical and scientific data can be authorised and supplied as medicines in Ireland (see HPRA’s report: Cannabis for Medical Use - A Scientific Review). At present there are no authorised medicines in Ireland that contain CBD as the only active ingredient. Accordingly, CBD products currently being sold for consumer use are not approved for the prevention or treatment of medical conditions or symptoms associated with such conditions.
Professors William Emboden, Loran Anderson, and Harvard botanist Richard E. Schultes and coworkers also conducted taxonomic studies of Cannabis in the 1970s, and concluded that stable morphological differences exist that support recognition of at least three species, C. sativa, C. indica, and C. ruderalis. For Schultes, this was a reversal of his previous interpretation that Cannabis is monotypic, with only a single species. According to Schultes' and Anderson's descriptions, C. sativa is tall and laxly branched with relatively narrow leaflets, C. indica is shorter, conical in shape, and has relatively wide leaflets, and C. ruderalis is short, branchless, and grows wild in Central Asia. This taxonomic interpretation was embraced by Cannabis aficionados who commonly distinguish narrow-leafed "sativa" strains from wide-leafed "indica" strains.
The Haleigh's Hope Act was signed by Georgia's Governor in 2016. This law has made the use of cannabis oil legal, however, it cannot contain any more than 5% THC. It can also only be used for medical reasons. CBD products from Every Day Optimal contain 0% THC and their items can only be used for medical purposes. The state believes that CBD can have an amazing impact on the lives of people all across the U.S. who are suffering from debilitating health problems.
Truly! I found out through import/export contacts that I could actually buy CBD not only in 55-gallon drums but in those massive containers like gas comes in .. just for a few thousand bucks!! I knew right then, if I had the money, I’d be ripping off the suckers there by the thousands – but I didn’t have the money, and probably .. maybe … wouldn’t REALLY want to do that! LOL Frankly, I cannot blame the sellers anymore. PT Barnum said it best, “There’s a sucker born every minute.” And if we suckers don’t wise the hell up, we almost deserve to have our money taken from our pockets.
Doctors advise pregnant women not to use any drugs because they might harm the growing fetus. Although one animal study has linked marijuana use to loss of the fetus very early in pregnancy, two studies in humans found no association between marijuana use and early pregnancy loss. More research is necessary to fully understand the effects of marijuana use on pregnancy.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
2014 saw a flurry of interest in Cannabidiol in particular, with a slew of states successfully passing CBD only legislation after mounting pressure from many numbers of families with children suffering from intractable Epilepsy resulted in the fast tracking of Cannabidiol laws in more than 10 U.S. states. The Cannabidiol issue is proving to be quite popular politically as it allows politicians to get behind the "won't get you high" side of the CBD story while temporarily dancing around the looming issues of future medical marijuana programs that are pending or have been proposed in many of these states, as well as the national movement towards approval for medicinal and recreational use on a large scale.